If you work in medical device quality and you have tried using GxP software designed for pharmaceutical companies, you know the frustration. The terminology is wrong (pharma talks about batch records; devices talk about design controls), the regulatory framework is wrong (21 CFR Part 211 vs 21 CFR Part 820, soon to be ISO 13485 alignment under the QMSR), and the workflow assumptions are wrong (pharma validates manufacturing processes; devices validate design, manufacturing, and the device itself). Device companies need GxP software that understands their world — not pharma software with the labels changed.
How medical device validation differs from pharma validation
The fundamental difference is the role of design controls. In pharma, validation focuses primarily on manufacturing processes and the computerised systems that support them. In medical devices, validation starts with design — design verification and design validation under 21 CFR Part 820 (and soon the QMSR) are the foundation. Software as a Medical Device (SaMD) adds another layer: the device itself may be software, which means software validation is not just about the tools you use — it is about the product you sell.
The risk framework is different too. Pharma uses GAMP 5 categories and ICH Q9 risk assessment. Devices use ISO 14971 risk management with a hazard-based approach that maps directly to patient harm through the device. Your GxP software needs to support ISO 14971 risk assessments natively, not force you to map device risks into a pharma risk framework that does not fit.
The MDR and IVDR impact on device validation software
The EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have significantly increased the validation and documentation burden for device companies selling into Europe. The technical documentation requirements under MDR Annex II and III are more extensive than under the previous directives, the clinical evidence requirements are stronger, and the post-market surveillance obligations are more demanding. For device companies using GxP software, this means the platform needs to support the full MDR documentation lifecycle — not just manufacturing validation, but design history file management, clinical evaluation support, and post-market surveillance data tracking. Clinical Evaluation Reports alone can be hundreds of pages, and the platform needs to maintain traceability between clinical evidence, risk analysis, and design requirements throughout the device lifecycle.
Software as a Medical Device: when the product is the validation
SaMD companies face a unique challenge: the software product itself needs to be validated as both a medical device (under the appropriate regulatory framework) and as a computerised system (under CSA/CSV requirements). The IEC 62304 software lifecycle standard adds specific requirements for software development processes, and the FDA's AI/ML guidance introduces additional considerations for SaMD that uses artificial intelligence. Your GxP software platform needs to manage both dimensions: the product validation lifecycle (design controls, V&V, design transfer) and the quality system validation lifecycle (the tools and systems your team uses to develop and manufacture the device). GxP Copilot handles the quality system validation side, generating risk-based test cases and maintaining Live RTM for every computerised system in your quality infrastructure.
What device companies should look for in GxP software
- ISO 14971 native risk assessment. Not FMEA bolted onto a pharma risk framework — genuine hazard-based risk assessment that traces from device hazards through harm scenarios to risk controls.
- Design control support. The ability to manage design inputs, design outputs, verification, and validation within the same platform that handles your quality system validation.
- MDR/IVDR documentation readiness. Technical documentation templates and traceability structures that align with MDR Annex II and III requirements.
- IEC 62304 alignment. If you develop software, your platform should support the IEC 62304 software lifecycle with appropriate documentation and traceability.
- Part 11 and Annex 11 compliance. Electronic signatures, audit trails, and access controls that satisfy both US and EU requirements.
Why most pharma GxP software does not fit devices
The honest answer is that pharma and device validation have diverged enough that a single platform rarely serves both well. Pharma GxP software is optimised for process validation, cleaning validation, and computerised system validation in a manufacturing context. Device GxP software needs to additionally handle design controls, product risk management, clinical evaluation, and the intersection of product development with quality system management. GxP Copilot focuses on the quality system validation side — the LIMS, eQMS, MES, and ERP systems that device companies use — and does it with AI Risk Assessment that can be configured for ISO 14971 alignment. For the product side (design controls, product V&V), most device companies need a dedicated design control platform. The two work together, and Live RTM provides the traceability bridge between them.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.